Metronomic oral gemcitabine for cancer therapy
Use of gemcitabine, including in self-emulsifying orally administered dosage forms for treatment, such as inducing regression or inhibiting growth, of tumors in a patient such as a human. Gemcitabine is orally administered in a metronomic manner.
Saved in:
| Main Authors | , , |
|---|---|
| Format | Patent |
| Language | English |
| Published |
12.01.2023
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Use of gemcitabine, including in self-emulsifying orally administered dosage forms for treatment, such as inducing regression or inhibiting growth, of tumors in a patient such as a human. Gemcitabine is orally administered in a metronomic manner. |
|---|---|
| AbstractList | Use of gemcitabine, including in self-emulsifying orally administered dosage forms for treatment, such as inducing regression or inhibiting growth, of tumors in a patient such as a human. Gemcitabine is orally administered in a metronomic manner. |
| Author | Hsueh, Shu-Piing Hsu, Chang-Shan Hao, Wei-Hua |
| Author_xml | – fullname: Hao, Wei-Hua – fullname: Hsueh, Shu-Piing – fullname: Hsu, Chang-Shan |
| BookMark | eNrjYmDJy89L5WTQ800tKcrPy8_NTFbIL0rMUUhPzU3OLElMysxLVUjLL1JITsxLTi1SKMlILUosqORhYE1LzClO5YXS3Awqbq4hzh66qQX58anFBYnJqXmpJfGOoUYGhuZG5sYmlqZOTkbGRCoDAAeHLdA |
| ContentType | Patent |
| DBID | EVB |
| DatabaseName | esp@cenet |
| DatabaseTitleList | |
| Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Chemistry Sciences |
| ExternalDocumentID | AU2017273495BB2 |
| GroupedDBID | EVB |
| ID | FETCH-epo_espacenet_AU2017273495BB23 |
| IEDL.DBID | EVB |
| IngestDate | Fri Jul 19 12:52:40 EDT 2024 |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | false |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-epo_espacenet_AU2017273495BB23 |
| Notes | Application Number: AU20170273495 |
| OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230112&DB=EPODOC&CC=AU&NR=2017273495B2 |
| ParticipantIDs | epo_espacenet_AU2017273495BB2 |
| PublicationCentury | 2000 |
| PublicationDate | 20230112 |
| PublicationDateYYYYMMDD | 2023-01-12 |
| PublicationDate_xml | – month: 01 year: 2023 text: 20230112 day: 12 |
| PublicationDecade | 2020 |
| PublicationYear | 2023 |
| RelatedCompanies | INNOPHARMAX, INC |
| RelatedCompanies_xml | – name: INNOPHARMAX, INC |
| Score | 3.4509535 |
| Snippet | Use of gemcitabine, including in self-emulsifying orally administered dosage forms for treatment, such as inducing regression or inhibiting growth, of tumors... |
| SourceID | epo |
| SourceType | Open Access Repository |
| SubjectTerms | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| Title | Metronomic oral gemcitabine for cancer therapy |
| URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230112&DB=EPODOC&locale=&CC=AU&NR=2017273495B2 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1LS8NAEB5KFfWmVfFVyaHkFm226SZ7KGJeFCFtkVZ6K252FUHT0kbEf-_MmmpPegsb2Mdk5_HN5psFaPGOL30MvR0hFXe8J547gVDKcSV3A4FbSpnrfLIB70-8u2l3WoPXNRfG1An9MMURUaNy1PfS2OvFbxIrNv9Wrq7lCzbNb9JxL7YrdMxouzI7DnvJaBgPIzuKEEnag3tKBZKnRjgQosHeokCaKu0nDyHxUhabTiXdh-0R9leUB1DTRQN2o_Xdaw3Yyaojb3ystG91CFeZpsQ18YgtItZbz_otR2yP4FZbGHxaOX3CpfXNqfo8glaajKO-gwPPftY5u51szDJknWOoF_NCn4DlM63yRyGZlG1PtYXs-irgLudo5oQSwSk0_-zq7J_357BHwqPUgssuoF4u33UTnW0pL42MvgDV44FG |
| link.rule.ids | 230,309,786,891,25594,76903 |
| linkProvider | European Patent Office |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3NT8IwFH8haMSbosYvdAey25SN0a0HYtzGMpUNYobhtti1GhMdBGaM_72vdSgnvTVt0o_Xvvf6e-2vBWiTrsMc3HoblHFi2E8kN1zKuWEyYroUlxRX3_nECYkm9u20N63B64oLo94J_VCPI6JG5ajvpbLX898gVqDuVi4v2Qtmza7CtB_oFTq25HK19MDrD8ajYOTrvo9IUk_uZShQemqEAx4a7A0HQaECSw-e5KXM151KuAObY6yvKHehJoomNPzV32tN2IqrI29MVtq33IOLWMjAteQRa5JYrz2LtxyxPYJboeHmU8vlFC60b07V5z60w0HqRwY2nP2MM7uerPXSs7oHUC9mhTgEzbEEzx8psxjr2LxDWc_hLjEJQTNHOXWPoPVnVcf_lJ9DI0rjYTa8Se5OYFsKUoYZTOsU6uXiXbTQ8ZbsTMnrCwashDA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=Metronomic+oral+gemcitabine+for+cancer+therapy&rft.inventor=Hao%2C+Wei-Hua&rft.inventor=Hsueh%2C+Shu-Piing&rft.inventor=Hsu%2C+Chang-Shan&rft.date=2023-01-12&rft.externalDBID=B2&rft.externalDocID=AU2017273495BB2 |